IB Net Payout Yields Model

Invest like me - only at Covestor.com

Glass House: Glass Problems

By -

 

  • Glass House has collapsed following the close of a SPAC transaction with Mercer Park Acquisition.
  • The company plans to cultivate up to 6.0 million sq. ft of greenhouse space in the highly competitive California market.
  • The stock has a limited market cap now, but the company has an unappealing business model focused on large scale cannabis cultivation.
  • Looking for more investing ideas like this one? Get them exclusively at Out Fox The Street. Learn More »
Glass House Brands (OTC:GLASF) has fallen victim to a couple of negative trends: SPACs and cannabis in general. While these trends are hurting the stock, the biggest problem is a focus on consolidating the highly competitive California cannabis market. My investment thesis is Neutral on the stock due to this focus of repeating the issues of the Canadian cannabis market.

Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please review the disclaimer page for more details. 

Update - Nov. 18

Some very negative comments on California overproduction from the WM Tech. (MAPS) Q3'21 earnings call continue to confirm that Glass House bought into the California cultivation market at exactly the wrong time. Investors must avoid this cannabis stock for now. 


-While licenses continue to be issued across our end markets, licensed density is not where it needs to be in the pace of license issuance remained sluggish, which is contributing to a thriving illicit market. And further, there has been a lot written in the press about how producers are dealing with the current supply glut, by in some cases diverting products to unlicensed market channels at significant price discounts, which is only further fueling the consumer demand shift.

-California, which is our largest market at just over 60% of revenue have lower end market retail sales in Q3 versus Q2 of this year. We believe that deceleration was a result of consumer demand shifting from licensed to non-licensed channels as producers, offloaded excess inventory to deal with the supply glut, resulting in significant price differentials between licensed versus non-licensed channels.

Comments

Post a Comment

Popular posts from this blog

Occidental: Still Producing Too Much Oil

By -
Image
Though oil continues plunging, the oil giants continue producing more. For Q4, Occidental Petroleum (OXY) had roughly flat production. The worst part is that OXY plans to grow production by 2% to 4% in 2016. The stock has held up somewhat strong, but the inability to turn off the spigot remains troubling. Disclosure: No positions mentioned. Please review the disclaimer page for more details. 
Read more

ChargePoint: Low Quality Beat

By -
Image
  ChargePoint beat FQ2'22 revenue estimates, but the losses are mounting. The company guided up FY22 numbers partly due to acquisitions. The stock still trades at an estimated 21x FY23 number leaving limited upside for the stock and reinforcing why venture funds sold 13.8 million shares. Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our model portfolio.  Learn More » After  solid FQ2'22 earnings ,  ChargePoint Holdings  ( CHPT ) has seen a nice bump in the stock. Now investors have to confront the valuation divide and deal with the past insider sales likely leading to future sales on any stock rallies. My  investment thesis  remains very Bearish on the EV charging station stock on any rallies into the mid-$20s. Read the full article on Seeking Alpha.  Disclosure: No position mentioned. Please review the disclaimer page for more details.  Update - Sept. 8 Be cautious when analysts struggle to make the bullish case on expen
Read more

Aurora Cannabis: Deal Or No Deal

By -
Aurora Cannabis was left out of the major deal making in 2018. The cannabis company updated FQ2 guidance to revenues of $50 to $55 million with a continued focus on pure production growth. The stock is down as the market is becoming less impressed with commodity farming operations due to the prime Oregon example. The stock is below key resistance at $5.40 as medical cannabis patient totals failed to impress. As the end of 2018 came and went,   Aurora Cannabis   ( ACB ) was a notable absentee from the deal making in the cannabis market. Just about all of the other major Canadian cannabis players got large investments or signed up powerful partnerships, but the related stocks didn't generally maintain rallies following the deals. Based on the early legalization data in Canada and Oregon, the best option for Aurora Cannabis might actually be selling production capacity while the Canadian market remains hot. Read the full article on Seeking Alpha.  Disclosure: No
Read more